Trinity Biotech (TRIB) Total Debt (2016 - 2025)
Trinity Biotech's Total Debt history spans 15 years, with the latest figure at $84.8 million for Q2 2025.
- On a quarterly basis, Total Debt rose 26.03% to $84.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $84.8 million, a 26.03% increase, with the full-year FY2024 number at $74.0 million, up 82.23% from a year prior.
- Total Debt hit $84.8 million in Q2 2025 for Trinity Biotech, up from $74.0 million in the prior quarter.
- Over the last five years, Total Debt for TRIB hit a ceiling of $84.8 million in Q2 2025 and a floor of $31000.0 in Q4 2021.
- Historically, Total Debt has averaged $52.2 million across 5 years, with a median of $47.6 million in 2022.
- Biggest five-year swings in Total Debt: surged 142806.45% in 2022 and later plummeted 35.47% in 2023.
- Tracing TRIB's Total Debt over 5 years: stood at $31000.0 in 2021, then surged by 142806.45% to $44.3 million in 2022, then decreased by 8.28% to $40.6 million in 2023, then surged by 82.23% to $74.0 million in 2024, then increased by 14.46% to $84.8 million in 2025.
- Business Quant data shows Total Debt for TRIB at $84.8 million in Q2 2025, $74.0 million in Q4 2024, and $66.4 million in Q3 2024.